Reliable access to repeat INR or anticoagulation clinic if warfarin adjustments
Same-week lab plan
Treatment
General hemostatic strategy
Treatment framework
Local control and procedural hemostasis
Topical tranexamic acid for epistaxis
Nasal packing or cautery as indicated
Blood component therapy guided by labs and bleeding severity
RBC transfusion for symptomatic anemia or shock
Plasma, fibrinogen, platelets based on deficits
Anticoagulant reversal based on agent and bleeding site
Critical site bleeding includes intracranial, intraspinal, pericardial, retroperitoneal
Warfarin reversal
Warfarin-associated major bleeding
Four-factor prothrombin complex concentrate
Dose based on INR and body weight per institutional protocol
Common dosing framework 25 to 50 units/kg with maximum per product label
Repeat INR 30 to 60 minutes after infusion completion
Class I recommendation in many society guidelines for life-threatening VKA bleeding
Faster INR correction compared with plasma
Vitamin K
10 mg IV slow infusion for major bleeding
Onset 4 to 6 hours with sustained effect
Repeat dosing based on INR trend
Plasma if PCC unavailable
15 mL/kg as initial dose
Volume overload risk and slower correction
Direct oral anticoagulant reversal
Factor Xa inhibitor major bleeding
Andexanet alfa when available and criteria met
Dosing based on agent, last dose, and time since last dose per product protocol
Bolus followed by 2-hour infusion
Thrombotic event risk and need for restart planning
Class IIa recommendation in some guidelines for life-threatening bleeding
Four-factor PCC when andexanet unavailable or not indicated
50 units/kg IV once commonly used in practice
Consider repeat based on clinical course and labs
Thrombosis risk counseling and monitoring
Dabigatran major bleeding
Idarucizumab
5 g IV as two consecutive 2.5 g doses
Rapid neutralization of dabigatran effect
Consider repeat dose in rebound with renal failure and ongoing bleeding
Hemodialysis consideration
Severe renal failure with persistent dabigatran effect
Heparin and LMWH reversal
Unfractionated heparin bleeding
Protamine sulfate
Dose based on heparin units received in prior 2 to 3 hours
Maximum single dose commonly 50 mg
Infuse slowly to reduce hypotension and anaphylactoid reactions
LMWH bleeding
Protamine partial reversal
Dose based on LMWH timing and dose
Incomplete anti-Xa reversal
Consider repeat protamine if ongoing bleeding and recent LMWH dose
Antiplatelet-associated bleeding
Antiplatelet therapy with major bleeding
Platelet transfusion in selected scenarios
Life-threatening bleeding with recent P2Y12 inhibitor and planned emergent surgery
Limited evidence and potential harm in spontaneous ICH contexts
Desmopressin for platelet dysfunction
0.3 mcg/kg IV over 15 to 30 minutes
Hyponatremia and fluid restriction monitoring
Consider in uremic platelet dysfunction and antiplatelet-associated ICH per local guideline
Fibrinogen replacement
Hypofibrinogenemia with active bleeding
Cryoprecipitate
Initial adult dose commonly 10 units
Recheck fibrinogen after administration
Target at least 1.5 to 2.0 g/L in major bleeding
Fibrinogen concentrate if available
Dose based on desired increment and body weight
Faster delivery and lower volume than cryoprecipitate
Plasma replacement
Plasma indications in bleeding
Multiple factor deficiency with bleeding and prolonged PT or aPTT
DIC with bleeding and prolonged PT
Liver failure with bleeding and procedural needs
Dosing
15 to 20 mL/kg initial dose
Reassess coag tests and clinical bleeding
Platelet thresholds in bleeding
Platelet transfusion targets
Major active bleeding
Target at least 50 x10^9/L
Intracranial hemorrhage or neurosurgery
Target at least 100 x10^9/L
Massive transfusion
Empiric platelets per MTP with adjustment by counts or TEG
DIC management
DIC with bleeding strategy
Trigger treatment
Early sepsis management bundle
Obstetric source control if placental abruption or retained products
Component therapy guided by bleeding and labs
Platelets to target at least 50 x10^9/L in bleeding
Fibrinogen replacement to target at least 1.5 g/L
Plasma for prolonged PT with active bleeding
Anticoagulation considerations
If predominant thrombosis and no active bleeding, individualized heparin strategy with hematology
Tranexamic acid
TXA use in selected bleeding states
Trauma within 3 hours of injury
1 g IV over 10 minutes then 1 g IV over 8 hours
Mortality benefit demonstrated in large pragmatic trials
Postpartum hemorrhage
1 g IV over 10 minutes
Second 1 g dose if bleeding continues after 30 minutes or recurs within 24 hours
Contraindications and cautions
Active intravascular clotting with high thrombotic risk
Dose adjustment in severe renal impairment
Acquired hemophilia and factor inhibitor emergencies
Suspected acquired hemophilia A with major bleeding
Mixing study pattern
Failure to correct aPTT with mix suggests inhibitor
Hemostatic agents
Recombinant activated factor VII 90 mcg/kg IV every 2 to 3 hours until hemostasis
Activated prothrombin complex concentrate 50 to 100 units/kg IV every 8 to 12 hours
Immunosuppression initiation with hematology
Steroids with or without cyclophosphamide or rituximab
Procedure planning in coagulopathy
Procedural bleeding mitigation
Central line selection
Ultrasound-guided compressible site preferred
Pre-procedure targets individualized by bleeding risk
Platelets and fibrinogen optimization for high-risk procedures
Avoid routine correction of mildly elevated INR in stable cirrhosis without bleeding
Special Populations
Pregnancy
Pregnancy-related considerations
Physiologic coagulation changes
Higher fibrinogen baseline with pregnancy
Increased thrombotic risk with reversal agents
Postpartum hemorrhage coagulopathy
Early TXA within 3 hours of onset
Fibrinogen replacement early if low or falling rapidly
Anticoagulant use
LMWH common with partial protamine reversibility
Warfarin generally avoided but possible postpartum
Geriatric
Older adult considerations
Higher anticoagulant exposure prevalence
Polypharmacy and interaction risk
Increased intracranial bleed risk
Lower threshold for CT head after falls
Renal impairment affecting DOAC clearance
Dabigatran and factor Xa inhibitor accumulation risk
Pediatrics
Pediatric considerations
Weight-based dosing for reversal agents and blood components
PCC, protamine, TXA dosing per kg
Congenital bleeding disorders more common relative to adults
Hemophilia and vWD evaluation pathway
Child protection considerations
Bruising pattern inconsistent with history requires safeguarding workflow
Background
Epidemiology
Population patterns
Anticoagulant-associated bleeding increasing with aging populations
DOAC use prevalent in atrial fibrillation and VTE
Inherited bleeding disorders prevalence
Hemophilia A rare and X-linked
von Willebrand disease most common inherited bleeding disorder
Pathophysiology
Hemostasis overview
Primary hemostasis
Platelet adhesion and aggregation
von Willebrand factor role in platelet adhesion
Secondary hemostasis
Coagulation cascade generating thrombin and fibrin
Vitamin K dependent factors II, VII, IX, X
Fibrinolysis
Plasmin-mediated clot breakdown
Hyperfibrinolysis contributing to traumatic coagulopathy
Common acquired coagulopathy mechanisms
DIC
Widespread thrombin generation with consumption of platelets and factors
Secondary fibrinolysis with elevated D-dimer
Liver disease
Reduced synthesis of procoagulant and anticoagulant proteins
Rebalanced hemostasis with bleeding and thrombosis risk
Therapeutic Considerations
Reversal principles
Match reversal to agent and bleeding severity
Critical site bleeding requires immediate reversal regardless of lab appearance
Thrombosis risk after reversal
Plan for anticoagulant restart timing with specialty input
Goal-directed transfusion
Use fibrinogen and platelet targets to avoid overtransfusion
Viscoelastic testing improves targeting where available
Evidence and guideline framing
Class I principle
Immediate reversal for life-threatening anticoagulant-associated bleeding supported by consensus and observational outcomes
Class IIa principle
Specific antidotes preferred when available for qualifying DOAC bleeds
Patient Discharge Instructions
Copy discharge instructions
Discharge instructions for resolved minor bleeding with coagulopathy risk
Medication plan
Clear instructions on holding or restarting anticoagulant
Avoid NSAIDs unless specifically advised
Follow-up
INR check date and location if on warfarin
Anticoagulation clinic or prescriber follow-up within 1 to 3 days if dose changed
Return to ED immediately
Any head injury or new headache while on anticoagulant
Vomiting blood or black tarry stools
Large-volume rectal bleeding
Shortness of breath, chest pain, fainting, or severe weakness
Rapidly enlarging bruising or swelling
New neurologic symptoms
Activity guidance
Avoid contact sports and high-fall-risk activities until cleared
Use soft toothbrush and avoid aggressive flossing if mucosal bleeding tendency
References
Clinical guidelines and evidence sources
Key references
Anticoagulant reversal society guidelines including ACC, AHA, ISTH, and hematology consensus statements
Warfarin major bleeding reversal recommendations including PCC plus IV vitamin K
DOAC major bleeding reversal recommendations including specific antidotes when available
ISTH guidance on DIC diagnosis and ISTH overt DIC scoring system
Serial scoring for monitoring progression and response
Trauma hemorrhage evidence for TXA timing within 3 hours
Standard dosing 1 g then 1 g infusion regimen
Obstetric hemorrhage evidence for TXA use
Early administration and repeat dosing criteria
Source file
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.